NewsRoom Articles - Page 5 of 154 - PsychedelicNewsWire (PNW)

MondayDec 16, 2024 10:00 am

New Approaches to Psychedelic Clinical Trials Could Overcome Regulatory Hurdles

Lykos Therapeutics was earlier this year denied approval for their MDMA formulation developed to treat post-traumatic stress disorder. The FDA advisory panel that rejected the application cited various issues as their basis, including sexual misconduct during the clinical trials, concerns about the drug’s potential for abuse, and a failure to submit data requested. Soon after, Lykos let go of over 70% of its workforce. Following these developments, Compass Pathways PLC (NASDAQ: CMPS) recently announced that it’d be delaying its phase III trial results reporting timeline to make certain that it could endure scrutiny associated with trial blinding. Compass Pathways, which…

WednesdayDec 11, 2024 10:00 am

Psilocybin Could Improve Sleep, Mental Health

Psilocybin is a psychoactive compound that naturally occurs in some species of hallucinogenic mushrooms. When ingested, this compound is converted into psilocin and interacts with serotonin receptors in the brain. This interaction results in altered mood, perception, and cognition and may produce vivid auditory and visual experiences as well as profound spiritual and/or emotional insights. Now a new study has found that psilocybin may help improve sleep quality and reduce symptoms of depression. This isn’t the first study to investigate the therapeutic effect of psilocybin on mental health conditions either. Various studies have found that this psychedelic compound has the…

MondayDec 09, 2024 10:00 am

New Study Seeks to Understand How Jewish Community Views Psychedelics

Rabbi Zac Kamenetz has long been interested in psychedelics, despite growing up being terrified of drugs. How the rabbi viewed psychedelics shifted after his first experience with psilocybin in 2017, during an NYU and Johns Hopkins study for religious professionals. Since then, his interest in the substances has continued to grow, even inspiring him to set up a non-profit in 2020. The non-profit in question, Shefa, educates members of the Jewish community about the rewards and risks associated with using psychedelics. Last month, Shefa announced that it’d be collaborating with Emory University to investigate the perspective of Jewish Americans on…

WednesdayDec 04, 2024 10:00 am

Psilocybin Shows Promise in Treating Eating Disorders

Anorexia nervosa is a common eating disorder characterized by distorted body image, extreme weight loss, and an extreme fear of gaining weight. Conventional treatments like nutritional rehabilitation and cognitive-behavioral therapy aren’t always successful, with some patients struggling with lifelong symptoms. This has prompted researchers to investigate the effectiveness of alternative therapies like psychedelic medicine. A clinical trial conducted last year by scientists from the University of California, San Diego evaluated the therapeutic potential and safety of psilocybin in treating anorexia nervosa in ten participants, all of whom were diagnosed according to the DSM-5 criteria. Psilocybin is the psychoactive compound found…

WednesdayNov 27, 2024 10:00 am

Animal Study Shows Psilocybin Boosts Optimism Long-Term

Psilocybin is a naturally occurring psychedelic compound that can be found in more than two hundred species of mushrooms. A new study has found that psilocybin may heighten engagement and optimism in tasks, providing insight into the drug’s potential in managing depression. Depression is a mental health condition characterized by a persistent feeling of sadness. Individuals with depression may lack motivation to engage with the outside world and often leads to withdrawal. Numerous studies have demonstrated psilocybin’s potential in managing symptoms of depression. Despite this, the mechanisms that drive the drug’s therapeutic effects remain unclear. The objective of this latest…

MondayNov 25, 2024 10:00 am

Psychedelics Could Help Smokers Quit

Tobacco is used by more than one billion people in the world. So it comes as no surprise that tobacco use disorder is highly prevalent. Tobacco contains nicotine, an addictive drug that quickly boosts an individual’s mood. It also makes an individual want to use it more while also making it hard for them to quit. Halting the use of tobacco is hard, primarily because of the disorder’s withdrawal symptoms, like irritability and anxiety. A recently published review of studies on psychedelics and the use of tobacco has concluded that psychedelics may help combat tobacco use disorder. Of all the…

WednesdayNov 20, 2024 10:00 am

Psychedelics Task Force in Vermont Calls for Education on Harm Reduction

A recently released report has determined that psilocybin possesses the potential to help manage mental health conditions like anxiety and depression in the context of end-of-life care and severe illness. The report was compiled by a task force in Vermont established earlier this year under S.114 by Governor Phil Scott. The eight-person group was tasked with reviewing studies and evidence of public health risks and benefits of clinical psychedelic-assisted therapy and giving recommendations on how and whether the state of Vermont should regulate legal access to psychedelics like MDMA and psilocybin. This is in addition to assessing the programs and…

MondayNov 18, 2024 10:00 am

Study Suggests Relaxation Best Predicts Impact of Psychedelic Therapy

A new study has investigated how effective psychedelic-assisted therapy is in managing various treatment-resistant mental conditions. The researchers determined that these therapy sessions, particularly those that involved psilocybin or LSD, substantially improved symptoms of depression. They also found that individuals who were relaxed during their sessions experienced noticeable effects. Prior to their study, the researchers posited that having a positive experience during one’s therapy session or feeling relaxed contributed to the therapeutic effects of psychedelic therapy. For their study, the researchers obtained data from 2 groups; twenty-eight patients taking part in psychedelic-assisted therapy and twenty-eight healthy participants who were part…

WednesdayNov 13, 2024 10:00 am

Australian Study Finds Psychologists Positive Towards Psychedelic-Assisted Therapy

A new study has found that psychedelic-assisted therapy is viewed by psychologists as a life-changing tool that has the potential to facilitate emotional breakthroughs and psychological insights for individuals with a range of mental conditions. The study was carried out by researchers at Griffith University, who interviewed twenty psychologists from different parts of Australia. Jordan Negrine, a Ph.D. candidate with the institution’s school of Applied Psychology, was the study’s lead researcher. Mr. Negrine stated that the participants demonstrated both caution and enthusiasm when asked about the therapeutic potential of psychedelic-assisted therapy. However, he continued, the psychologists also displayed limited awareness…

MondayNov 11, 2024 2:30 pm

Massachusetts Voters Say No to Measure Seeking to Decriminalize Psychedelics

Voters in the state of Massachusetts have rejected a ballot measure that would’ve removed penalties for the sharing, possession, and non-commercial production of a range of naturally occurring psychedelics. Results from the election night show that 57% of voters voted No to Question 4, which would’ve permitted individuals aged 21 and above to use psilocyn, psilocybin, mescaline, ibogaine, and DMT. Eligible persons would’ve also been able to cultivate a personal amount of these psychedelics and been able to help others in those activities. The limits for possession stipulated in the measure were 1g for psilocybin, psilocyn or DMT, 30g for…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000